Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the anticancer effect of anlotinib in combination strategies remains a clinical challenge. Metformin is an oral agent...

Full description

Bibliographic Details
Main Authors:	Zhongling Zhu, Teng Jiang, Huirong Suo, Shan Xu, Cai Zhang, Guoguang Ying, Zhao Yan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Pharmacology
Subjects:	non-small cell lung cancer anlotinib metformin AMP-activated protein kinase reactive oxygen species
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.712181/full

Similar Items

Metformin improves memory via AMPK/mTOR-dependent route in a rat model of Alzheimer’s disease
by: Reza Mehraban, et al.
Published: (2024-03-01)

Metformin Mitigates Cartilage Degradation by Activating AMPK/SIRT1-Mediated Autophagy in a Mouse Osteoarthritis Model
by: Chenzhong Wang, et al.
Published: (2020-07-01)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
by: Guoshuang Shen, et al.
Published: (2018-09-01)

Future of Metformin Administration in Sepsis Management
by: Mojtaba Mojtahedzadeh, et al.
Published: (2017-02-01)

Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks
by: Vincenzo Sorrenti, et al.
Published: (2022-07-01)

Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways
by: Liemei Guo, et al.
Published: (2021-03-01)

Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases
by: Ming-Rui Du, et al.
Published: (2022-04-01)

Changes in AMPK activity induces cellular senescence in human dental follicle cells
by: Christian Morsczeck, et al.
Published: (2023-02-01)

Effect of metformin on semen quality
by: Saleem Ali Banihani

Anlotinib treatment for rapidly progressing pediatric embryonal rhabdomyosarcoma in the maxillary gingiva: a case report
by: Bo Ding, et al.
Published: (2024-10-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

Effects of the peripheral CB1 receptor antagonist JD5037 in mono— and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension
by: Patryk Remiszewski, et al.
Published: (2022-09-01)

Metformin Attenuates Silica-Induced Pulmonary Fibrosis by Activating Autophagy via the AMPK-mTOR Signaling Pathway
by: Shu-xian Li, et al.
Published: (2021-08-01)

The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution
by: Zheng C, et al.
Published: (2020-09-01)

Metformin Induces Autophagy via the AMPK-mTOR Signaling Pathway in Human Hepatocellular Carcinoma Cells
by: Gao C, et al.
Published: (2020-07-01)

Anlotinib helps alleviate radiation pneumonitis: A case report
by: Jiazhen Chen, et al.
Published: (2021-12-01)

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
by: Jiaojiao Suo, et al.
Published: (2021-12-01)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
by: Jiuhui Xu, et al.
Published: (2023-06-01)

Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells
by: Zhongling Zhu, et al.
Published: (2023-08-01)

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial
by: Hui Zhu, MD, et al.
Published: (2022-06-01)

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis
by: Mengzhang Xie, et al.
Published: (2024-05-01)

Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis
by: Parkyong Song, et al.
Published: (2021-02-01)

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
by: Cheng JD, et al.
Published: (2020-07-01)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
by: Nan Jin, et al.
Published: (2022-04-01)

Rosiglitazone Mitigates Dexamethasone-Induced Depression in Mice via Modulating Brain Glucose Metabolism and AMPK/mTOR Signaling Pathway
by: Aisha Alhaddad, et al.
Published: (2023-03-01)

Decreased AMP‐activated protein kinase (AMPK) function and protective effect of metformin in neonatal rat pups exposed to hyperoxia lung injury
by: Abha Yadav, et al.
Published: (2020-09-01)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
by: Zhujun Liu, et al.
Published: (2022-05-01)

Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis
by: You G, et al.
Published: (2020-02-01)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
by: Ran Zuo, et al.
Published: (2020-11-01)

Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease
by: Ji-Won Kim, et al.
Published: (2022-01-01)

Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway
by: Qiuling Chen, et al.
Published: (2022-11-01)

Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases
by: Zeyu Liu, et al.
Published: (2024-10-01)

Acute Administration of Metformin Protects Against Neuronal Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury via Regulation of the AMPK/CREB/BDNF Pathway
by: Ke Liu, et al.
Published: (2022-04-01)

A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan
by: Ibrahim Mohammed, et al.
Published: (2021-08-01)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
by: Shasha Wang, et al.
Published: (2022-05-01)

Corrigendum: Acute Administration of Metformin Protects Against Neuronal Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury via Regulation of the AMPK/CREB/BDNF Pathway
by: Ke Liu, et al.
Published: (2022-06-01)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
by: Yishi Zhang, et al.
Published: (2023-05-01)

mTOR Dysregulation, Insulin Resistance, and Hypertension
by: Silviu Marcel Stanciu, et al.
Published: (2024-08-01)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
by: Liu Z, et al.
Published: (2021-02-01)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
by: Yurou Ji, et al.
Published: (2022-12-01)